Resverlogix Amends Debenture Terms Amidst Therapy Development
Company Announcements

Resverlogix Amends Debenture Terms Amidst Therapy Development

Story Highlights

Resverlogix (TSE:RVX) has released an update.

Resverlogix Corp. has extended its secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group, pushing the maturity date to May 13, 2026, while also increasing the interest rate from 12% to 18% and removing Hepalink’s conversion privileges. The amendments, which also include additional reporting requirements and the continuation of normal business operations, are pending approval by the Toronto Stock Exchange and Resverlogix shareholders. This financial restructuring aims to support Resverlogix’s development of epigenetic therapies for chronic diseases.

For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskResverlogix Showcases Apabetalone’s Heart Health Benefits
TipRanks Canadian Auto-Generated NewsdeskResverlogix Secures Shareholder Approval and Debenture Extension
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App